Andere talen INVO Bioscience, Inc.

Aandelen

INVO

US44984F4019

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 08-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,93 ^USD	0,00%		-7,00%	-31,11%

16/04	INVO Bioscience, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
2023	NAYA Biosciences Inc. kondigt de publicatie aan van nieuwe gegevens voor zijn CD38-gericht Flex-NK Bispecifiek Antilichaam in de American Society of Hematology's Blood Journal	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Exploring Emerging Companies with Key Developments Garnering Attention: INBS, INVO, VTAK, RCAT, GCTK	22/04
Top Premarket Decliners	18/04
Sector Update: Health Care Stocks Retreating Late Afternoon	17/04
Top Midday Gainers	17/04
Traders Digest Earnings After Rate-Driven Losses, US Equity Futures Rebound Slightly	17/04
Top Premarket Gainers	17/04
INVO Reports Fourth Quarter and Full Year 2023 Financial Results	16/04
INVO Bioscience : Reports Fourth Quarter and Full Year 2023 Financial Results - Form 8-K	16/04
INVO Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04
INVO Bioscience, Inc. announced that it has received $0.5 million in funding from FirstFire Capital Management LLC	08/04
INVO Bioscience, Inc. announced that it expects to receive $0.5 million in funding from FirstFire Capital Management LLC	05/04
INVO Bioscience : Private Placement - Form 8-K	01/04
Certain Options of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	09/02
Certain Warrants of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	09/02
Certain Common Stock of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	09/02
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors	17/01
INVO Bioscience, Inc. announced that it expects to receive $5 million in funding from NAYA Biosciences Inc.	29/12
INVO Bioscience : Submission of Matters to a Vote of Security Holders - Form 8-K	28/12
NAYA Biosciences Announces Publication Of New Data For Its CD38-Targeted Flex-NK Bispecific Antibody in The American Society of Hematology s Blood Journal	12/12
NAYA Biosciences Inc. Announces Publication of New Data for its CD38-targeted Flex-NK Bispecific Antibody in the American Society of Hematology's Blood Journal	11/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen INVO Bioscience, Inc.

Aandelen

INVO

US44984F4019

Andere talen

Filters